Meeting
2023 ASCO Annual Meeting
A phase 2 open-label study of conditionally active biologic ozuriftamab vedotin (BA3021) in failed PD-1/L1 treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Authors
Alan Loh Ho
Memorial Sloan Kettering Cancer Center, New York, NY
Alan Loh Ho , Douglas Adkins , Jochen H. Lorch , Jacob Stephen Thomas , Jaspreet Singh Grewal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT05271604
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS6107)
DOI
10.1200/JCO.2023.41.16_suppl.TPS6107
Abstract #
TPS6107
Poster Bd #
96a
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
CMP-001-007: Open-label, phase 2 study of intratumoral CMP-001 + pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma.
First Author: Deborah J.L. Wong
Poster
2023 ASCO Annual Meeting
Nanoparticle albumin-bound (nab) paclitaxel in combination with nivolumab as treatment of recurrent or metastatic head and neck squamous-cell carcinoma (RM-HNSCC) that progressed on a PD-1 inhibitor: A single-arm, phase 2 trial.
First Author: Jared Cohen
Poster
2022 ASCO Annual Meeting
Penpulimab plus anlotinib in patients with recurrent or metastatic head and neck squamous cell carcinoma after the failure of first-line platinum-based chemotherapy: A single-arm, multicenter, phase 2 study.
First Author: Changgong Zhang